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Introduction
Levosimendan is a calcium sensitiser that enhances
myocardial contractility without increasing myocardial
oxygen consumption or adversely affecting diastolic
function. Whilst theoretically attractive, lack of outcome
data in critically ill patients means that it is not yet
established in intensive care practice. We have been
using levosimendan on our Intensive Care Unit (ICU)
for more than 6 years and the data presented here
represents one of the largest case series on the use of
levosimendan in this setting.
Objectives
To retrospectively analyse the cases of patients on a
general ICU who were treated with levosimendan.
Methods
Our electronic patient record was used to identify
patients who had been treated with levosimendan
between 2009 and 2014. Patients’ notes were analysed for
demographic and clinical data. Subgroups for each
answer were predefined and the best fit answer was
decided by the investigator. A second search (2011-2013)
was used to identify 2 matched control populations:
acute myocardial infarction (AMI) and pneumonia. A
chi-squared test was used to see if there was a difference
in ICU outcomes between the matched controls and
those treated with levosimendan.
Results
Over the 5 year period levosimendan was used in 90
patient cases. Exactly half the patients died in the ICU
(Table 1).
72% of patients had cardiac monitoring to aid diagno-
sis and response to treatment; 28% were treated on clin-
ical grounds alone.
81% of patients were mechanically ventilated and 77%
were already on vasoactive infusions.
3 patients were documented to have aortic stenosis, a
contraindication to levosimendan.
33% of patients had a >20% fall in systolic blood pres-
sure associated with the use of levosimendan. 6% had a
new arrhythmia.
For patients with cardiac failure associated with AMI
there was a statistically significant difference between
the ICU mortality of those treated with or without levo-
simendan, favouring levosimendan. There were insuffi-
cient data to draw conclusions about those with
pneumonia (Table 3).
Conclusions
In this case series, the most common indication for
levosimendan use was heart failure secondary to AMI.
We observed an ICU survival benefit in using levosi-
mendan in this group of patients. This finding is sup-
ported by the RUSSLAN study that showed a short-
term survival benefit to using levosimendan in thisRoyal Devon and Exeter Hospital, Intensive Care Medicine, Exeter, United
Kingdom
Table 1
ICU survivors (Mean
(range))
ICU non-survivors (Mean
(range))
No. patients 45 45
Age 61 (28-83) 71 (17-89)
APACHE-2 score 21 (8-36) 20 (0-37)
Table 2 Indications for the use of levosimendan.
No. cases
Indication ICU
survivors
ICU non-
survivors
Ischaemic heart failure 26 25
Sepsis induced cardiomyopathy 10 14
Acutely decompensated chronic heart
failure
6 5
Right heart failure 1 3
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patient group [1]. Whilst there is, to date, no evidence
for a long-term mortality benefit in patients with AMI
induced cardiac failure, there is supporting evidence for
patients with acute decompensation of their chronic car-
diac insufficiency [2].
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Table 3
Control Levosimendan p-value
Pneumonia
APACHE-2 score 23.7 23.9
ICU mortality 41/168 = 24% 5/9 = 56% N/A
AMI
APACHE-2 score 16.7 19.8
ICU mortality 47/78 = 60% 25/51 = 49% p = 0.0247
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